SEARCH RESULTS

4815 RESULTS

E2814

THERAPEUTICS Eisai Co., Ltd. Immunotherapy (passive) Tau In December 2019, Eisai began a Phase 1 trial testing the safety and tolerability of a single intravenous infusion in healthy adults. Secondary outcomes included serum and CSF pharmacokinetics and immunogenicity ...

Current Filters

  • Date Range : Nov 2020 to Feb 2021 x

Remove all filters

Filter By

DATE RANGE
  • All
  • Past 7 Days
  • Past 30 Days
  • Past 90 Days
  • Past 12 Months
  • Specific Dates
    1. From
      To

TYPE